Gyre Therapeutics, a US-based commercial-stage biopharmaceutical company focused on innovative therapies for organ fibrosis, has announced the appointment of Dr. Dan Weng to its Board of Directors, effective August 18, 2025.

Dr. Weng has served as President and Chief Executive Officer of Medelis, a specialty oncology contract research organisation (CRO), since 2018. From 2013 to 2017, he was Chairman, President, and Chief Executive Officer of EPS International Holding Co., a subsidiary of EPS Holdings, Inc., a global CRO where he oversaw significant growth, both organically and through M&A in Asia, and played an active role in corporate strategy and investor relations.

Prior to that, Dr. Weng held executive positions at international CROs, including MedPace, Inc., ICON Plc, PharmaNet Development Group, and Quintiles Translational Corp. He also held research positions at Harvard Medical School, Massachusetts General Hospital, and the University of California.

Dr. Weng holds an MD from the Tongji Medical University, and an MA in Health Planning, Policy and Management from the University of Leeds.

“We are pleased to welcome Dr. Weng to our Board at this pivotal time in Gyre’s evolution. Dan brings nearly four decades of experience in managing global clinical trials across a range of therapeutic areas,” said Ping Zhang, Executive Chairman and Interim Chief Executive Officer of Gyre.

“His strategic insight and extensive regulatory experience will be invaluable as we continue to expand our commercial reach and advance our multi-national pipeline,” Zhang added.

Headquartered in San Diego, CA, Gyre Therapeutics is primarily focused on the development and commercialisation of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH) in the United States.